The stock of Bright Minds Biosciences Inc. (NASDAQ:DRUG) last traded at $0.77, down -3.57% from the previous session.
Data from the available sources indicates that Bright Minds Biosciences Inc. (NASDAQ:DRUG) is covered by 1 analysts. The consensus rating among analysts is ‘Buy’. As we calculate the median target price by taking the range between a high of $9.09 and a low of $9.09, we find $9.09. Given the previous closing price of $0.79, this indicates a potential upside of 1050.63 percent. DRUG stock price is now -17.60% away from the 50-day moving average and -29.69% away from the 200-day moving average. The market capitalization of the company currently stands at $19.27M.
In total, 0 analysts have assigned it a hold rating, and 1 have given it a buy rating. Brokers who have rated the stock have averaged $9.09 as their price target over the next twelve months.
Insiders disposed of 10,000 shares of company stock worth roughly $7700.0 over the past 1 year. A total of 23.80% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in DRUG stock. A new stake in Bright Minds Biosciences Inc. shares was purchased by FIRST REPUBLIC INVESTMENT MANAGEMENT, INC. during the first quarter worth $9,000. TWO SIGMA INVESTMENTS, LP invested $8,000 in shares of DRUG during the first quarter. In the first quarter, BANK OF AMERICA CORP /DE/ acquired a new stake in Bright Minds Biosciences Inc. valued at approximately $8,000. TWO SIGMA SECURITIES, LLC acquired a new stake in DRUG for approximately $8,000. In total, there are 13 active investors with 2.23% ownership of the company’s stock.
With an opening price of $0.8000 on Tuesday morning, Bright Minds Biosciences Inc. (NASDAQ: DRUG) set off the trading day. During the past 12 months, Bright Minds Biosciences Inc. has had a low of $0.70 and a high of $4.75. As of last week, the company has a debt-to-equity ratio of 0.02, a current ratio of 8.10, and a quick ratio of 8.10. The fifty day moving average price for DRUG is $0.9297 and a two-hundred day moving average price translates $1.0896 for the stock.
The latest earnings results from Bright Minds Biosciences Inc. (NASDAQ: DRUG) was released for Jun, 2022.
Bright Minds Biosciences Inc.(DRUG) Company Profile
Bright Minds Biosciences Inc., a pre-clinical biosciences company, develops 5-HT (serotonin) medicines to improve the lives of patients with severe and life-altering diseases. Its portfolio of selective 5-HT receptor agonists comprises 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry. The company has collaboration with National Institutes of Health for the treatment of epilepsy; University of Texas Medical Branch to treat impulse control disorders, such as binge eating; and Medical College of Wisconsin. The company was incorporated in 2019 and is headquartered in Vancouver, Canada.